| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
HuR[1]
|
|---|---|
| ln Vitro |
CMLD-2 (1-75 μM; 24-72 h) suppresses the viability of thyroid cancer cells [2]. In H1299 and A549 cells, CMLD-2 (20–30 μM; 24-48 h) activates caspases and causes apoptotic cell death [3]. In H1299 and A549 cells, CMLD-2 (30 μM; 24-48 hours) causes mitochondrial disruption and G1 cell cycle arrest [3]. In H1299 cells, CMLD-2 (30 μM; 24-48 hours) decreases HuR and HuR-regulated mRNA and protein expression [3]. The directional migratory capacity of SW1736, 8505C, BCPAP, and K1 cells is decreased by CMLD-2 (35 μM; 72 hours). MAD2 mRNA levels in SW1736, 8505C, BCPAP, and K1 cells can be markedly decreased by CMLD-2 [2].
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: SW1736, 8505C, BCPAP and K1 cells Tested Concentrations: 1, 5, 10, 25, 35, 50, 75 μM Incubation Duration: 24, 48, 72 hrs (hours) Experimental Results: decreased the viability of all the four cell lines when used at 35, 50 and 75 μM concentration and at different time points. Apoptosis Analysis[3] Cell Types: H1299, A549, H1975, HCC827, MRC-9 and CCD16 cells Tested Concentrations: 20, 30 μM Incubation Duration: 24, 48 hrs (hours) Experimental Results: Marked activated the caspase-9 and -3 in lung tumor cells. Induce the cleavage of PARP in lung tumor cells. Dramatically increased the annexin-V-positive staining in lung tumor cells. Cell Cycle Analysis[3] Cell Types: H1299, A549, MRC-9 and CCD16 cells Tested Concentrations: 30 μM Incubation Duration: 24, 48 hrs (hours) Experimental Results: Induced greater G1 phase cell cycle arrest in H1299 and A549 cells than in MRC-9 and CCD16 cells. Western Blot Analysis[3] Cell Types: H1299, A549, H1975, HCC827, CCD16 and MRC-9 cells Tested Concentrations: 20, 30 μM Incubation Duration: 24, 48 hrs (hours) Experimental Results: Diminished protei |
| References |
|
| Molecular Formula |
C31H31NO6
|
|---|---|
| Molecular Weight |
513.58
|
| Exact Mass |
513.215
|
| Elemental Analysis |
C, 72.50; H, 6.08; N, 2.73; O, 18.69
|
| CAS # |
958843-91-9
|
| PubChem CID |
16746438
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
741.3±60.0 °C at 760 mmHg
|
| Flash Point |
402.1±32.9 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.606
|
| LogP |
5.59
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
38
|
| Complexity |
839
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PROGRNRRJJYCNX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H31NO6/c1-35-22-13-11-21(12-14-22)23(17-27(33)32-15-7-8-16-32)29-25(36-2)19-26(37-3)30-24(18-28(34)38-31(29)30)20-9-5-4-6-10-20/h4-6,9-14,18-19,23H,7-8,15-17H2,1-3H3
|
| Chemical Name |
5,7-dimethoxy-8-(1-(4-methoxyphenyl)-3-oxo-3-(pyrrolidin-1-yl)propyl)-4-phenyl-2H-chromen-2-one
|
| Synonyms |
958843-91-9; CMLD-2; MLS000879470; SMR000465530; CMLD2; CMLD 2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50 mg/mL (97.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9471 mL | 9.7356 mL | 19.4712 mL | |
| 5 mM | 0.3894 mL | 1.9471 mL | 3.8942 mL | |
| 10 mM | 0.1947 mL | 0.9736 mL | 1.9471 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
